I am delighted to announce my participation in the prestigious BIO-EUROPE SPRING 2025, a key event for innovation in biotechnology and life sciences, taking place in Milan from March 17 to 20, 2025.
At this event, I will have the opportunity to present our two flagship projects, which have the potential to revolutionize the treatment of brain tumors and neurodevelopmental disorders, including autism. These breakthroughs, made possible through the synergy of Neurochlore, B&A Oncomedical, and B&A Biomedical, pave the way for new therapeutic solutions for complex diseases that currently lack effective treatments.
Our Projects:
- An Innovative Combined Approach to Treat Brain Tumors:
We are introducing a combined therapy that targets both tumor hyperexcitability and cancer cell destruction. Through our collaboration with Professor F. Berger and his team in Grenoble, we have obtained unprecedented results on tumors directly extracted from patients. In addition to identifying two promising candidates—Bumetanide and Mebendazole—we have developed, in partnership with world-renowned experts, new molecules capable of specifically targeting tumor hyperexcitability. These new compounds exhibit a unique and even more potent effect compared to their parent molecule. This patented approach could pave the way for more effective treatments for tumors with limited therapeutic options today. - Identifying Treatment Responders Using Machine Learning for Neurodevelopmental Disorders:
Autism spectrum disorders (ASD) and other neurodevelopmental conditions exhibit high clinical heterogeneity, leading to the failure of all Phase 3 clinical trials. We have directly faced this challenge in our own trials. To address this, we leveraged Machine Learning algorithms to analyze our trial data and identify subgroups of patients who respond positively to treatment. This approach allowed us to identify 30–40% of participants who demonstrated a positive response.
This data-driven stratification paves the way for a targeted Phase 3 trial with refined inclusion criteria, significantly increasing the likelihood of success. Moreover, this approach has the potential to transform how clinical trials are conducted and enhance treatment efficacy for patients—not only in autism but also in other complex diseases.
This event is a key opportunity to establish strategic partnerships and secure funding to accelerate our research. Our goal: to launch large-scale clinical trials and bring these innovations closer to real-world treatments.
I hope to return with major breakthroughs and, above all, to move one step closer to my ultimate ambition: developing effective therapies to treat, or even cure, autism and brain tumors.
Meet me at Booth #017 to explore our projects in detail.
Join my talk on Monday, March 17, at 1:00 PM at the Exhibit Hall Stage for an in-depth presentation of our research, results, and latest advancements.
